Tractament del CPNM metastàtic EFGR positiu amb inhibidors d’ITK en primera línia: informe d'avaluació de resultats
Abstract
Lung cancer (LC) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of new cases of LC for 2019 was 29,503 cases. LC remains the leading cause of cancer death in Spain in both sexes, with an overall five-year survival of 13%, which decreases to 1% in the metastatic stage. Non-small cell lung cancer (NSLC) accounts for approximately 80% - 90% of all LC and is classified according to histology into adenocarcinoma (≈ 40%), large cell carcinoma (15%), and squamous or epidermoid cell carcinoma (≈ 25-30%).
Keywords
Non-microcytic lung cancer; Targeted therapy; Health results
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Tractament del CPNM metastàtic EFGR positiu amb inhibidors d’ITK en primera línia: informe d'avaluació de resultats. Barcelona: Servei Català de la Salut; 2021.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/6197This item appears in following collections
The following license files are associated with this item: